VARIATIONS OF THE EFFICIENCY OF BIOLOGICAL THERAPY IN VULGAR PSORIASIS
With the rapid understanding of the pathogenesis of psoriasis, the number of treatment options available for moderate to severe form has also increased. In this paper, we focus on the efficacy and safety profile of biological products in patients with psoriasis. In addition, we discuss the impact of biologics on comorbidities caused by psoriasis, considering several factors associated with the patient and the condition, and aim to review therapeutic opportunities in terms of biologic therapies and their variety. Material and methods: A retrospective study that has as a sample a group of 113 patients diagnosed with psoriasis vulgaris, under investigation by the Dermato-Venerology Clinic at the “Sf. Spiridon” County Clinical Emergency Hospital Iași. All these patients are under biological therapy and were admitted to the clinic between 2017-2021. Results: Of the 113 patients proposed for the study, 63% were male (n = 71) and 37% female (n = 42). Of the total sample, the preponderance of the age range was that of the ‘> 40 years’ range with a total of 85% (n = 96) consisting of 61 men and 35 women (p = 0.019, statistically significant result). Conclusions: With the introduction of new biological substances and the discontinuation of others, an update of biological substances in psoriasis is delayed. Understanding the benefits, risks and monitoring of patients with biologic therapies is becoming increasingly important for the dermatologist.
2. Ronholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci 2017; 18(11): 2297.
3. Strober B, Karki C, Mason M, Guo N, Holmgren SH, Greenberg JD, et al. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: results from the Corrona Psoriasis Registry. J Am Acad Dermatol 2018; 78(2): 323-332.
4. Amin M, No DJ, Egeberg A, Wu JJ. Choosing first-line biologic treatment for moderate-to-severe psoriasis: what does the evidence say? Am J Clin Dermatol 2018; 19(1): 1-13.
5. Kamata M, Tada Y. Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review. Int J Mol Sci 2020; 21(5): 1690.
6. Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol 2019; 80: 251-265.
7. Dougados M, Wei JC, Landewe R, et al. Efficacy and safety of ixekizumab through 52 weeks in two phase 3,randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis 2020; 79: 176-185.
8. Brownstone ND, Hong J, Mosca M, et al. Biologic Treatments of Psoriasis: An Update for the Clinician. Biologics 2021; 15: 39-51.
9. Burlando M, Herzum A, Carmisciano L, Cozzani E, Parodi A. Biological therapy in genital psoriasis in women. Dermatol Ther 2020; 33(1): e13110.
10. Van der Heijde D, Deodhar A, FitzGerald O et al. 4-year results from the RAPID-PsA phase 3 randomized placebo-controlled trial of certolizumab pegol in psoriatic arthritis. RMD Open 2018; 4(1): e000582.
11. Gordon K, Korman N, Frankel E, et al. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol 2006; 54(3): 101-111.
12. Gottlieb AB, Blauvelt A, Thaçi D, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol 2018; 79(2): 302-314.
13. Iskandar IYK, Warren RB, Lunt M, et al. Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol 2018; 138(4): 775-784.
14. Mourad A, Straube S, Armijo-Olivo S, Gniadecki R. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis. Br J Dermatol 2019;181(3):450-458.
15. Ellis AG, Flohr C, Drucker AM. Network meta-analyses of systemic treatments for psoriasis: a critical appraisal: Original Articles: Jabbar-Lopez ZK, Yiu ZZN,Ward V et al. Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis. J Invest Dermatol 2017; 137: 1646-1654.
16. Sawyer LM, Cornic L, Levin LA, Gibbons C, Moller AH, Jemec GB. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. J. Eur Acad Dermatol Venereol 2019; 33: 355-366.
17. Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2017; 12(12): CD011535.
18. Papp KA, Lebwohl MG. Onset of Action of Biologics in Patients with Moderate-to-Severe Psoriasis. J Drugs Dermatol 2017; 17: 247-250.
19. Yao CJ, Lebwohl MG. Onset of Action of Antipsoriatic Drugs for Moderate-to-Severe Plaque Psoriasis: An Update. J Drugs Dermatol 2019; 18: 229-233.
20. Strober B, Menter A, Leonardi C, et al. Efficacy of Risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. J Eur Acad Dermatol Venereol 2020; 34(12): 2830-2838.
21. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
22. Yeung H, Wan J, Van Voorhees AS et al. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol 2013; 68: 64-72.
23. Grajdeanu I, Statescu L, Vata D, et al. Imaging techniques in the diagnosis and monitoring of psoriasis (Review). Exp Ther Med 2019; 18(6): 4974-4980.
24. Solovăstru GL, Vâţă D, Batog AH, Siriac O, Alupoaiei A, Diaconu D. Comorbidities in psoriatic patients of Iaşi Dermatological Clinic from 2004-2008. Rev Med Chir Soc Med Nat Iasi 2009; 113(3): 751-756.
25. Grechin C, Solovăstru LG, Vâță D, Pătrașcu AI, Grăjdeanu AI, Porumb Andrese E. Inflammatory marker alteration in response to systemic therapies in psoriasis. Exp Ther Med 2020; 20: 42-46.
26. Stîncanu A, Andrese E, Stãtescu L, Vâță D, Solovăstru GL. Leptin - a systemic inflammation marker in vulgar psoriasis associated with metabolic syndrome. Experimental and clinical study. Dermato Venerol 2014; 59: 209-216.
27. Porumb‑Andrese E, Vâță D, Postolică R et al. Association between personality type, affective distress profile and quality of life in patients with psoriasis vs. patients with cardiovascular disease. Exp Ther Med 2019; 18(6): 4967-4973.
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.
COPYRIGHT TRANSFER FORM FOR
REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /
THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI
We, the undersigned authors of the manuscript entitled
warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.
- we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
- the manuscript does not break the intellectual property rights of any other person.
- we have read the submitted version of the manuscript and we are fully responsible for the content.
Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):
N.B. All the authors must sign this form